Laurel Hollow, NY – Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of California, Davis have reached a new breakthrough in pancreatic cancer research—eight years in the making. It could help slow the disease’s deadly spread. In 2017, as a postdoc in CSHL’s Tuveson lab, Chang-il Hwang and collaborators from...
Latest News
New York – Pancreatic cancer is not just one disease, but that’s the way it is currently treated. New findings from Tannishtha Reya’s lab could help pave the way for a change. Though most pancreatic cancers are classified as pancreatic ductal adenocarcinoma (PDAC) several other subtypes exist. “Everyone gets the...
BOSTON, Mass. – Tuberculosis (TB) is often overlooked in developed countries such as the United States, but this bacterial infection remains one of the deadliest diseases globally and results in millions of deaths annually. Deaths can occur even with treatment, sometimes because of drug resistance in TB bacteria and other...
Baton Rouge, Louisiana – Diabetes affects more than 1 in 10 — or more than 38 million — Americans. People with diabetes who keep their blood sugar levels in the near-normal range generally have a much lower risk of developing diabetes complications such as heart, kidney, and eye diseases. The...
ITHACA, N.Y. – Scientists have long believed that a newborn’s immune system was an immature version of an adult’s, but new research from Cornell University shows that newborns’ T cells – white blood cells that protect from disease – outperform those of adults at fighting off numerous infections. These results...
Boston, Mass. – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear cell...
Charleston, SC – A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity. Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the...
Two biotechs are shoring up their pipelines and commercial aspirations, tacking on a clinical-stage rare disease drug and a preclinical cancer med, respectively. Fortress Biotech-founded Avenue Therapeutics is adding on a phase 1/2-stage asset from AnnJi Pharmaceutical for the treatment of spinal and bulbar muscular atrophy (SBMA). Financial details are...
Grenoble. France – Researchers from the Bhogaraju Group at EMBL Grenoble have gained new insights into how a cancer-relevant family of proteins bind their targets. The results of the study, published in The EMBO Journal, could potentially help in the development of drugs against certain chemotherapy- and radiotherapy-resistant cancers. The...
MANHASSET, N.Y. — A new study led by scientists at Northwell Health’s Feinstein Institutes for Medical Research has revealed that defects in different ribosomal proteins lead to a rare blood disorder called Diamond-Blackfan Anemia Syndrome (DBAS) through surprisingly different pathways. This discovery helps explain why patients with DBAS can experience varied...